On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials.
The first efficacy trials--named STEP--of a T cell vaccine against HIV/AIDS began in 2004.The unprecedented structure of these trials raised new modeling and statistical challenges.Is it plausible that memory T cells, as opposed to antibodies, can actually prevent infection? If they fail at prevention, to what extent can they ameliorate disease? An